Participation in disclosing opinions on Clinical Considerations for Efficacy and Safety Assessment

e-Participation Events

About Project

This guidance provides recommendations on the clinical data requirements for Human medicinal and biological products. It applies to data supporting new applications for drug, biologic, generic drug applications and type II variations regarding changes to therapeutic indications.

09/01/2023 - 09/03/2023

webmaster@sfda.gov.sa

View Event

Was this page useful?

Please tell us why (You can select multiple options)

Content is relevant

It was well written

The layout made it easy to read

Other reason

If you have more feedback?

I'm

Male

Female

I prefer not to say

This information is requested for national analytical purposes for improving the unified national platform, and the measure the satisfaction/ dissatisfaction between the two genders.

For more information you may review e-participation statement and rules of engagement.